These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 23774991

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Impact of Oncotype DX on treatment decisions in ER-positive, node-negative breast cancer with histologic correlation.
    Biroschak JR, Schwartz GF, Palazzo JP, Toll AD, Brill KL, Jaslow RJ, Lee SY.
    Breast J; 2013; 19(3):269-75. PubMed ID: 23614365
    [Abstract] [Full Text] [Related]

  • 3. Is oncotype DX recurrence score (RS) of prognostic value once HER2-positive and. low-ER expression patients are removed?
    Milburn M, Rosman M, Mylander C, Tafra L.
    Breast J; 2013; 19(4):357-64. PubMed ID: 23701403
    [Abstract] [Full Text] [Related]

  • 4. Impact of oncotype DX recurrence score in the management of breast cancer cases.
    Nguyen MT, Stessin A, Nagar H, D'Alfonso TM, Chen Z, Cigler T, Hayes MK, Shin SJ.
    Clin Breast Cancer; 2014 Jun; 14(3):182-90. PubMed ID: 24486121
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
    Asad J, Jacobson AF, Estabrook A, Smith SR, Boolbol SK, Feldman SM, Osborne MP, Boachie-Adjei K, Twardzik W, Tartter PI.
    Am J Surg; 2008 Oct; 196(4):527-9. PubMed ID: 18809056
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Factors influencing Oncotype DX use in the management of early breast cancer: a single centre experience.
    Zhu X, Dent S, Paquet L, Zhang T, Graham N, Song X.
    Eur J Cancer; 2014 Oct; 50(15):2544-9. PubMed ID: 25129366
    [Abstract] [Full Text] [Related]

  • 10. Changing paradigms in breast cancer management: introducing molecular genetics into the treatment algorithm.
    Rayhanabad JA, Difronzo LA, Haigh PI, Romero L.
    Am Surg; 2008 Oct; 74(10):887-90. PubMed ID: 18942607
    [Abstract] [Full Text] [Related]

  • 11. Comparison of efficacy of 95-gene and 21-gene classifier (Oncotype DX) for prediction of recurrence in ER-positive and node-negative breast cancer patients.
    Naoi Y, Kishi K, Tsunashima R, Shimazu K, Shimomura A, Maruyama N, Shimoda M, Kagara N, Baba Y, Kim SJ, Noguchi S.
    Breast Cancer Res Treat; 2013 Jul; 140(2):299-306. PubMed ID: 23884597
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
    Habel LA, Shak S, Jacobs MK, Capra A, Alexander C, Pho M, Baker J, Walker M, Watson D, Hackett J, Blick NT, Greenberg D, Fehrenbacher L, Langholz B, Quesenberry CP.
    Breast Cancer Res; 2006 Jul; 8(3):R25. PubMed ID: 16737553
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
    Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J.
    Value Health; 2010 Jul; 13(4):381-7. PubMed ID: 20412544
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.
    Dodson A, Okonji D, Assersohn L, Rigg A, Sheri A, Turner N, Smith I, Parton M, Dowsett M.
    Breast Cancer Res Treat; 2018 Feb; 168(1):249-258. PubMed ID: 29128896
    [Abstract] [Full Text] [Related]

  • 20. The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.
    Stemmer SM, Klang SH, Ben-Baruch N, Geffen DB, Steiner M, Soussan-Gutman L, Merling S, Svedman C, Rizel S, Lieberman N.
    Breast Cancer Res Treat; 2013 Jul; 140(1):83-92. PubMed ID: 23801158
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.